Authors
Aliya A Khan, Hugues Allard-Chamard, Mikameh Kazem, Sarah Khan, Thanu N Ruban
Published in
Expert opinion on biological therapy. Aug 13, 2026. Epub Aug 13, 2026.
Abstract
Following the approval of the first denosumab biosimilar in Canada, patients receiving long-term denosumab treatment for osteoporosis may be switched from the reference biologic to the biosimilar. Supporting patient-reported satisfaction following a switch will be critical to ensure treatment adherence, and foster patient confidence and ongoing acceptance of denosumab biosimilars.
This cross-sectional, multicenter, real-world survey in Canada included adults with osteoporosis switched from reference (Prolia®, Amgen) to biosimilar (Jubbonti®, Sandoz) denosumab (n = 435). Data collected included demographics, disease and treatment history, and patient experience and satisfaction with switching. Key endpoints assessed overall satisfaction with the switch (based on a five-point scale) and the perceived importance of economic benefits and improved treatment access.
Most patients (83.1%) expressed satisfaction with the switch, and 84.8% reported being satisfied with the explanation provided about the biosimilar. Clear and adequate communication was significantly associated with overall switch satisfaction (p < 0.001). Better affordability of a biosimilar was considered important by 72.7% of respondents.
In this real-world survey, respondents reported high satisfaction with the switch from reference to biosimilar denosumab, particularly when the transition was accompanied by clear communication from their healthcare provider. Findings should be interpreted considering limitations inherent to cross-sectional survey research.
PMID:
42596614
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 13
- Comments 0